Back to Search Start Over

A multicentre outcome analysis to define global benchmarks for donation after circulatory death liver transplantation.

Authors :
Schlegel A
van Reeven M
Croome K
Parente A
Dolcet A
Widmer J
Meurisse N
De Carlis R
Hessheimer A
Jochmans I
Mueller M
van Leeuwen OB
Nair A
Tomiyama K
Sherif A
Elsharif M
Kron P
van der Helm D
Borja-Cacho D
Bohorquez H
Germanova D
Dondossola D
Olivieri T
Camagni S
Gorgen A
Patrono D
Cescon M
Croome S
Panconesi R
Carvalho MF
Ravaioli M
Caicedo JC
Loss G
Lucidi V
Sapisochin G
Romagnoli R
Jassem W
Colledan M
De Carlis L
Rossi G
Di Benedetto F
Miller CM
van Hoek B
Attia M
Lodge P
Hernandez-Alejandro R
Detry O
Quintini C
Oniscu GC
Fondevila C
Malagó M
Pirenne J
IJzermans JNM
Porte RJ
Dutkowski P
Taner CB
Heaton N
Clavien PA
Polak WG
Muiesan P
Source :
Journal of hepatology [J Hepatol] 2022 Feb; Vol. 76 (2), pp. 371-382. Date of Electronic Publication: 2021 Oct 14.
Publication Year :
2022

Abstract

Background & Aims: The concept of benchmarking is established in the field of transplant surgery; however, benchmark values for donation after circulatory death (DCD) liver transplantation are not available. Thus, we aimed to identify the best possible outcomes in DCD liver transplantation and to propose outcome reference values.<br />Methods: Based on 2,219 controlled DCD liver transplantations, collected from 17 centres in North America and Europe, we identified 1,012 low-risk, primary, adult liver transplantations with a laboratory MELD score of ≤20 points, receiving a DCD liver with a total donor warm ischemia time of ≤30 minutes and asystolic donor warm ischemia time of ≤15 minutes. Clinically relevant outcomes were selected and complications were reported according to the Clavien-Dindo-Grading and the comprehensive complication index (CCI). Corresponding benchmark cut-offs were based on median values of each centre, where the 75 <superscript>th</superscript> -percentile was considered.<br />Results: Benchmark cases represented between 19.7% and 75% of DCD transplantations in participating centres. The 1-year retransplant and mortality rates were 4.5% and 8.4% in the benchmark group, respectively. Within the first year of follow-up, 51.1% of recipients developed at least 1 major complication (≥Clavien-Dindo-Grade III). Benchmark cut-offs were ≤3 days and ≤16 days for ICU and hospital stay, ≤66% for severe recipient complications (≥Grade III), ≤16.8% for ischemic cholangiopathy, and ≤38.9 CCI points 1 year after transplant. Comparisons with higher risk groups showed more complications and impaired graft survival outside the benchmark cut-offs. Organ perfusion techniques reduced the complications to values below benchmark cut-offs, despite higher graft risk.<br />Conclusions: Despite excellent 1-year survival, morbidity in benchmark cases remains high. Benchmark cut-offs targeting morbidity parameters offer a valid tool to assess the protective value of new preservation technologies in higher risk groups and to provide a valid comparator cohort for future clinical trials.<br />Lay Summary: The best possible outcomes after liver transplantation of grafts donated after circulatory death (DCD) were defined using the concept of benchmarking. These were based on 2,219 liver transplantations following controlled DCD donation in 17 centres worldwide. Donor and recipient combinations with higher risk had significantly worse outcomes. However, the use of novel organ perfusion technology helped high-risk patients achieve similar outcomes as the benchmark cohort.<br />Competing Interests: Conflict of interest The authors declare no conflicts of interest that pertain to this work. Please refer to the accompanying ICMJE disclosure forms for further details.<br /> (Copyright © 2021 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.)

Details

Language :
English
ISSN :
1600-0641
Volume :
76
Issue :
2
Database :
MEDLINE
Journal :
Journal of hepatology
Publication Type :
Academic Journal
Accession number :
34655663
Full Text :
https://doi.org/10.1016/j.jhep.2021.10.004